Then the phase 3 OCEANIC-AF, trial comparing the novel factor XI inhibitor asundexian (Bayer) vs the direct-acting oral anticoagulant apixaban in patients with atrial fibrillation was stopped ...

The literature reveals the connection between factor XI and fibrinolysis. [17] Fibrinolysis is inhibited by activated thrombin-activatable fibrinolysis inhibitor (TAFIa). The activation of ...